(Q36025876)

11 August 2017

Biological response modifier therapy for refractory childhood uveitis (English)

1 reference

11 August 2017

1 reference

Michael Gallagher

1

1 reference

11 August 2017

Karina Quinones

2

1 reference

11 August 2017

Rene Antonio Cervantes-Castañeda

3

1 reference

11 August 2017

Taygan Yilmaz

4

1 reference

11 August 2017

C Stephen Foster

5

1 reference

11 August 2017

language of work or name

English

0 references

publication date

7 June 2007

1 reference

British Journal of Ophthalmology

11 August 2017

1 reference

11 August 2017

91

1 reference

11 August 2017

10

1 reference

11 August 2017

1341-1344

1 reference

Adalimumab in the therapy of uveitis in childhood

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000999

Retrospective case review of pediatric patients with uveitis treated with infliximab

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000999

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000999

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000999

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000999

Cyclosporin A therapy in refractory non-infectious childhood uveitis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000999

Biologic agents for treating rheumatoid arthritis. Concepts and progress

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000999

Complications of corticosteroid and immunosuppressive drugs

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000999

Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000999

Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000999

Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000999

Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000999

Treatment of ocular inflammatory disorders with daclizumab

23 September 2018

1 reference

12 December 2020

A clinical trial of FK506 in refractory uveitis

1 reference

12 December 2020

Treatment of severe refractory uveitis with intravenous cyclophosphamide

1 reference

12 December 2020

Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents

1 reference

12 December 2020

Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series

1 reference

12 December 2020

Analysis of pediatric uveitis cases at a tertiary referral center

1 reference

12 December 2020

Favorable response to high-dose infliximab for refractory childhood uveitis

1 reference

12 December 2020

Adalimumab therapy for childhood uveitis

1 reference

12 December 2020

Identifiers

DOI

10.1136/BJO.2007.124081

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

17556427

1 reference